来源：新浪证券-红岸工作室 2月26日，五洲医疗涨0.02%，成交额3959.40万元，换手率2.35%，总市值28.38亿元。 异动分析 专精特新+医疗器械概念+人民币贬值受益 1、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 2、公司主营业务为一次性使用无菌输注类医疗器械的研发、生产、销售以及其他诊断、护理等相关医 疗用品的集成供应，产品为一次性使用无菌注射器(带针)、一次性使用无菌注射器(不带针)、一次性使 用无菌胰岛素注射器、输液器、输血器、注射针、胰岛素注射笔用针头、输液针、采血针、血压表、面 罩、导尿管。 3、根据2024年年报，公司海外营收占比为96.88%，受益于人民币贬值。 资料显示，安徽宏宇五洲医疗器械股份有限公司位于安徽省安庆市太湖县经济开发区观音路2号，成立 日期2011年4月15日，上市日期2022年7月5日，公司主营业务涉及一次性使用无菌输 ...

Core Viewpoint - The company, Wuzhou Medical, specializes in the research, production, and sales of disposable sterile infusion medical devices and has been recognized as a "specialized, refined, distinctive, and innovative" enterprise, benefiting from the depreciation of the RMB with a significant portion of its revenue coming from overseas sales [2][3]. Group 1: Company Overview - Wuzhou Medical focuses on disposable sterile infusion medical devices, including syringes, infusion sets, blood transfusion sets, and other related medical supplies [2]. - The company was established on April 15, 2011, and went public on July 5, 2022, with its main revenue sources being syringes (41.29%), medical puncture needles (25.51%), and infusion/blood transfusion devices (20.92%) [7]. - As of January 30, 2025, the number of shareholders increased by 0.32% to 5,381, while the average circulating shares per person decreased by 0.32% [7]. Group 2: Financial Performance - For the period from January to September 2025, Wuzhou Medical reported a revenue of 345 million yuan, representing a year-on-year growth of 0.82%, while the net profit attributable to the parent company was 18.51 million yuan, a decrease of 46.09% year-on-year [7]. - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8]. Group 3: Market Activity - On February 25, the stock price of Wuzhou Medical fell by 0.45%, with a trading volume of 24.91 million yuan and a turnover rate of 1.48%, resulting in a total market capitalization of 2.838 billion yuan [1]. - The stock has seen a net outflow of 1.3664 million yuan from major investors, indicating a reduction in holdings over the past three days [4][5].

Core Viewpoint - Wuzhou Medical has been recognized as a "specialized, refined, distinctive, and innovative" enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating its strong market position and innovation capabilities [2]. Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices and related medical supplies, including various types of syringes, infusion sets, and other medical instruments [2][7]. - The company was established on April 15, 2011, and went public on July 5, 2022, with its headquarters located in Anqing, Anhui Province [7]. - The revenue composition of Wuzhou Medical includes 41.29% from syringes, 25.51% from medical puncture needles, 20.92% from infusion and blood transfusion devices, and 12.28% from other products [7]. Group 2: Financial Performance - For the period from January to September 2025, Wuzhou Medical achieved a revenue of 345 million yuan, representing a year-on-year growth of 0.82%, while the net profit attributable to the parent company was 18.51 million yuan, a decrease of 46.09% year-on-year [7]. - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8]. Group 3: Market Position and Trends - Wuzhou Medical's overseas revenue accounts for 96.88%, benefiting from the depreciation of the Chinese yuan [3]. - The company is classified under the pharmaceutical and biological industry, specifically in the medical device and consumables sector, and is involved in various concept sectors including medical consumables and overseas expansion [7].

Core Viewpoint - Wuzhou Medical has shown a slight increase in stock price and is recognized as a "specialized, refined, distinctive, and innovative" enterprise, benefiting from the depreciation of the RMB and a strong overseas revenue stream [2][3]. Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices and related medical supplies, with a product range that includes various types of syringes, infusion sets, and other medical instruments [2][7]. - The company was established on April 15, 2011, and went public on July 5, 2022, with a current market capitalization of 2.857 billion yuan [1][7]. - As of January 20, the number of shareholders is 5,364, a decrease of 2.28%, with an average of 7,488 circulating shares per person, an increase of 2.33% [7]. Group 2: Financial Performance - For the period from January to September 2025, Wuzhou Medical achieved a revenue of 345 million yuan, representing a year-on-year growth of 0.82%, while the net profit attributable to the parent company was 18.51 million yuan, a decrease of 46.09% year-on-year [7]. - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8]. Group 3: Market Position and Trends - Wuzhou Medical's overseas revenue accounts for 96.88% of its total revenue, benefiting from the depreciation of the RMB [3]. - The company is recognized as a leader in its niche market, which enhances its competitiveness and stability within the supply chain [2].

Core Viewpoint - Wuzhou Medical has shown a slight increase in stock price and is benefiting from the depreciation of the RMB, with a significant portion of its revenue coming from overseas sales [1][3]. Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, including various types of syringes, infusion sets, and other medical supplies [2]. - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [2]. - As of January 20, the company reported a revenue of 345 million yuan for the first nine months of 2025, reflecting a year-on-year growth of 0.82%, while net profit decreased by 46.09% to approximately 18.51 million yuan [7]. Group 2: Financial Performance - The company's overseas revenue accounts for 96.88% of total revenue, benefiting from the depreciation of the RMB [3]. - The average trading cost of the stock is 42.76 yuan, with the current price near a support level of 41.29 yuan, indicating potential volatility [6]. - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8]. Group 3: Market Position and Shareholder Information - Wuzhou Medical operates under the pharmaceutical and medical device industry, focusing on medical consumables [7]. - As of September 30, 2025, the company saw a decrease in the number of shareholders by 2.28%, with an increase in average circulating shares per person by 2.33% [7][9].

Core Viewpoint - Wuzhou Medical's stock experienced a slight decline of 0.37% on February 2, with a total market capitalization of 2.71 billion yuan and a trading volume of 37.90 million yuan [1] Business Overview - The company specializes in the research, production, and sales of disposable sterile infusion medical devices, including various types of syringes, infusion sets, blood transfusion sets, and other related medical supplies [2] - Wuzhou Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [2] Financial Performance - As of the 2024 annual report, overseas revenue accounted for 96.88% of total revenue, benefiting from the depreciation of the Renminbi [3] - For the period from January to September 2025, Wuzhou Medical achieved a revenue of 345 million yuan, representing a year-on-year growth of 0.82%, while net profit attributable to shareholders decreased by 46.09% to 18.51 million yuan [7] Shareholder and Market Activity - As of January 20, the number of shareholders decreased by 2.28% to 5,364, with an average of 7,488 circulating shares per person, which increased by 2.33% [7] - The company has distributed a total of 81.60 million yuan in dividends since its A-share listing [8] - Notably, as of September 30, 2025, the fund "Noan Multi-Strategy Mixed A" exited the list of the top ten circulating shareholders [9]

Core Viewpoint - The company, Wuzhou Medical, experienced a decline of 1.44% in stock price on December 31, with a trading volume of 118 million yuan and a market capitalization of 2.89 billion yuan [1] Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, including various types of syringes, infusion sets, blood transfusion sets, and other medical supplies [2] - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [2] - As of October 20, the company reported a revenue of 345 million yuan for the period from January to September 2025, reflecting a year-on-year growth of 0.82%, while net profit attributable to shareholders decreased by 46.09% to 18.51 million yuan [7] Group 2: Financial Performance - The company's overseas revenue accounted for 96.88% of total revenue, benefiting from the depreciation of the Chinese yuan [3] - The average trading cost of the company's shares is 42.66 yuan, with the stock price approaching a resistance level of 43.15 yuan, indicating potential for upward movement if this level is surpassed [6] - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8] Group 3: Market Position and Trends - The company operates under the pharmaceutical and biological industry, specifically in the medical device and consumables sector, and is involved in various concept sectors including overseas expansion and specialized innovation [7] - As of September 30, 2025, the top ten circulating shareholders of Wuzhou Medical saw changes, with notable exits from major funds [9]

Core Viewpoint - Wuzhou Medical has seen a stock price increase of 1.39% with a trading volume of 106 million yuan and a market capitalization of 2.932 billion yuan, indicating positive market sentiment towards the company [1] Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, including various types of syringes, infusion sets, blood transfusion devices, and other medical supplies [2] - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong market position and innovation capabilities [2] - As of October 20, the company reported a revenue of 345 million yuan for the first nine months of 2025, reflecting a year-on-year growth of 0.82%, while the net profit attributable to shareholders decreased by 46.09% to 18.51 million yuan [7] Group 2: Financial Performance - The company's overseas revenue accounts for 96.88% of its total revenue, benefiting from the depreciation of the Renminbi [3] - The average trading cost of the stock is 42.63 yuan, with the current price approaching a resistance level of 43.15 yuan, indicating potential for upward movement if this level is surpassed [6] - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8] Group 3: Market Position - Wuzhou Medical operates under the pharmaceutical and biological industry, specifically in the medical device and consumables sector, and is involved in various concept sectors including overseas expansion and specialized innovation [7]

Core Viewpoint - The company, Wuzhou Medical, is engaged in the research, production, and sales of disposable sterile infusion medical devices, benefiting from the depreciation of the RMB and its classification as a "specialized, refined, distinctive, and innovative" enterprise [2][3]. Group 1: Company Overview - Wuzhou Medical specializes in disposable sterile infusion medical devices, including syringes, infusion sets, blood transfusion sets, and other related medical supplies [2]. - The company was established on April 15, 2011, and went public on July 5, 2022, with its main revenue sources being syringes (41.29%), medical puncture needles (25.51%), and infusion/blood transfusion devices (20.92%) [7]. - As of October 20, the number of shareholders increased by 17.31% to 5,489, while the average circulating shares per person decreased by 14.76% [7]. Group 2: Financial Performance - For the period from January to September 2025, Wuzhou Medical reported a revenue of 345 million yuan, representing a year-on-year growth of 0.82%, while the net profit attributable to the parent company was 18.51 million yuan, down 46.09% year-on-year [7]. - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8]. Group 3: Market Dynamics - The company has a high overseas revenue ratio of 96.88%, benefiting from the depreciation of the RMB [3]. - The stock experienced a slight decline of 0.02% on December 25, with a trading volume of 31.21 million yuan and a turnover rate of 1.87%, leading to a total market capitalization of 2.827 billion yuan [1].

Core Viewpoint - Wuzhou Medical has seen a stock price increase of 2.29% with a trading volume of 43.72 million yuan and a total market capitalization of 2.827 billion yuan, benefiting from its recognition as a "specialized, refined, distinctive, and innovative" enterprise and the depreciation of the RMB [1][2][3]. Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices and related medical supplies, including various types of syringes and infusion devices [2][7]. - The company was established on April 15, 2011, and went public on July 5, 2022, with its main revenue sources being syringes (41.29%), medical puncture needles (25.51%), and infusion/blood transfusion devices (20.92%) [7]. - As of October 20, 2023, the number of shareholders increased by 17.31% to 5,489, while the average number of circulating shares per person decreased by 14.76% [7]. Group 2: Financial Performance - For the period from January to September 2025, Wuzhou Medical reported a revenue of 345 million yuan, reflecting a year-on-year growth of 0.82%, while the net profit attributable to the parent company was 18.51 million yuan, a decrease of 46.09% year-on-year [7]. - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8]. Group 3: Market Position and Trends - Wuzhou Medical is recognized as a "little giant" enterprise, which signifies its strong innovation capabilities and high market share in niche markets, contributing to the stability and competitiveness of the supply chain [2]. - The company benefits significantly from overseas revenue, which accounts for 96.88% of its total revenue, particularly due to the depreciation of the RMB [3].